Market Cap | 117.16M | P/E | - | EPS this Y | 76.20% | Ern Qtrly Grth | - |
Income | -43.02M | Forward P/E | -3.72 | EPS next Y | -22.30% | 50D Avg Chg | -6.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -9.00% |
Dividend | N/A | Price/Book | 5.31 | EPS next 5Y | - | 52W High Chg | -46.00% |
Recommedations | 2.20 | Quick Ratio | 0.99 | Shares Outstanding | 13.05M | 52W Low Chg | 28.00% |
Insider Own | 21.56% | ROA | -183.39% | Shares Float | 10.24M | Beta | 1.73 |
Inst Own | 8.11% | ROE | -453.01% | Shares Shorted/Prior | 1.20M/1.55M | Price | 13.01 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 30,311 | Target Price | 32.40 |
Oper. Margin | - | Earnings Date | Nov 6 | Volume | 21,516 | Change | -3.84% |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
EF Hutton | Buy | Aug 15, 24 |
HC Wainwright & Co. | Buy | Aug 15, 24 |
EF Hutton | Buy | Aug 13, 24 |
HC Wainwright & Co. | Buy | Jul 17, 24 |
HC Wainwright & Co. | Buy | Jul 11, 24 |
Rodman & Renshaw | Buy | Jul 2, 24 |
HC Wainwright & Co. | Buy | Jun 12, 24 |
Rodman & Renshaw | Buy | Jun 4, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Maccecchini Maria-Luisa | President and CEO President and CEO | Feb 06 | Option | 0.14 | 52,755 | 7,386 | 1,040,489 | 02/08/23 |
Maccecchini Maria-Luisa | President and CEO President and CEO | Jan 14 | Option | 0.14 | 32,959 | 4,614 | 987,734 | 01/18/22 |